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Abstract
Background: Dysregulated CD44 expression characterizes most human cancers, including prostate cancer (PCa).
PCa loses expression of CD44 standard (CD44s) that is present in benign epithelium, and overexpresses the novel
splice variant isoform, CD44v7-10.
Methods: Using retroviral gene delivery to PC-3M PCa cells, we expressed luciferase-only, enforced CD44s re-
expression as a fusion protein with luciferase at its C-terminus or as a protein separate from luciferase, or knocked
down CD44v7-10 by RNAi. Invasion, migration, proliferation, soft agar colony formation, adhesion, Docetaxel
sensitivity, and xenograft growth assays were carried out. Expression responses of merlin, a CD44 binding partner,
and growth-permissive phospho-merlin, were assessed by western blot.
Results: Compared to luciferase-only PC-3M cells, all three treatments reduced invasion and migration. Growth and
soft agar colony formation were reduced only by re-expression of CD44s as a separate or fusion protein but not
CD44v7-10 RNAi. Hyaluronan and osteopontin binding were greatly strengthened by CD44s expression as a
separate protein, but not a fusion protein. CD44v7-10 RNAi in PC-3M cells caused marked sensitization to
Docetaxel; the two CD44s re-expression approaches caused minimal sensitization. In limited numbers of mouse
subcutaneous xenografts, all three alterations produced only nonsignificant trends toward slower growth
compared with luciferase-only controls. The expression of CD44s as a separate protein, but not a fusion protein,
caused emergence of a strongly-expressed, hypophosphorylated species of phospho-merlin.
Conclusion: Stable re-expression of CD44s reduces PCa growth and invasion in vitro, and possibly in vivo,
suggesting CD44 alterations have potential as gene therapy. When the C-terminus of CD44s is fused to another
protein, most phenotypic effects are lessened, particularly hyaluronan adhesion. Finally, CD44v7-10, although it was
not functionally significant for growth, may be a target for chemosensitization.
Background
About 30% of cases of prostate cancer (PCa) undergo
transition from quiescent to aggressive. In this transi-
tion, altered expression of adhesion glycoproteins such
as CD44 occurs allowing tumor cells to detach, interact
with proteins that digest stromal matrix, migrate
through matrix, and intravasate into lymphovascular
channels. CD44 is a transmembrane molecule encoded
by an alternately spliced gene. The standard (CD44s)
isoform is ubiquitous, but inclusion of one or more of
10 variant (v) exons lengthens the extracellular stem,
producing tissue-specific (CD44v) isoforms. CD44 is
involved in multiple cellular functions. Its N-terminus
enables cell-cell adhesion and binds hyaluronan and
other matrix ligands, while the C-terminus links the
cell’s membrane to actin and ankyrin in the cytoskele-
ton, modulating shape and motility.
In prior work, we isolated RNA from clinical PCa tis-
sues and discovered that expression of CD44v7-10
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sistently expressed in primary and metastatic PCa.
Androgen-independent PCa cell lines also strongly
expressed it[1-3]. Interference against CD44v7-10 caused
a 69% reduction in invasion index compared to
untreated control cells[3] and altered ligand-binding affi-
nities[4]. Moreover, PCa loses the splicing ability to pro-
duce the standard isoform expressed in benign prostate
[3,5,6], and certain variants other than CD44 v7-10[1,7].
Stable, virally altered CD44 expression has not been
tested in any system. We enacted transient CD44v7-10
RNAi in PC-3 cell variants using the plasmid U6pBS
which lacks a drug-resistance selection gene[3], and
later using pTracer with drug resistance and GFP signal
genes[4,8], and produced several phenotypic changes.
Others have also enacted transient plasmid transfection
of CD44s into PC-3 cells, causing reduced growth in
vitro and tumorigenicity in mouse xenografts[9].
Here, we perform the first comprehensive assessment
of two types of stable, retroviral CD44 alterations on PCa
cells and their functional effects. First, two CD44s re-
expression sequences were created–one translating to a
fusion protein comprising CD44s with luciferase at its
cytoplasmic, C-terminus, and the other expressing these
as two separate proteins. Second, a CD44v7-10 RNAi
sequence was expressed. Their potential for human gene
therapy was tested by in vitro invasion, attached growth,
anchorage-independent growth, and chemosensitization,
and by creating subcutaneous xenografts. Dephosphory-
lated merlin binds CD44 and inhibits growth, whereas
merlin is inactivated by phosphorylation to a growth-per-
missive state. Because one of the two CD44s re-expres-
sion transfectants has a free cytoplasmic -COOH tail and
the other a bound tail, we assessed whether merlin, a
binding partner of CD44’s tail, may be sterically hindered
from interaction with luciferase-fused CD44s.
Methods
Cell lines
Benign BPH-1 and 293T cells were from American Type
Culture Collection (Manassas, VA). PC-3M cells, a
metastasis-derived variant of PC-3, were from Dr. I. J.
Fidler, M.D. Anderson Cancer Center, Houston, TX.
The culture medium for PC-3M cells was RPMI 1640
(Invitrogen, Carlsbad, CA) with 10% fetal calf serum
(FCS) and antibiotics. 293T cells were in Dulbecco’s
modified Eagle medium with FCS. Cells were grown in
5% CO2 incubation at 37°C. For cell set-up, cells in a
flask were trypsinized, medium with serum was added
to neutralize trypsin, and cells were stained in Trypan
blue and counted by grid method[4].
Viral (Stable) CD44 Transfectants; Merlin Transfectants
Three constructs were made in Lentivector pLEX-MCS
(Open Biosystems, Huntsville, AL), which contains the
cytomegalovirus promoter, associated sequences, and
puromycin resistance gene. These were Lenti-lucifer-
ase, Lenti-CD44s-luciferase, and Lenti-CD44s-RSV-
luciferase (Figure 1). Lenti-luciferase was made by
inserting the luciferase fragment from a plasmid (gift
of Dr. J. Shen, Department of Radiation Oncology,
Univ. of Colorado Denver) behind CMV promoter. A
“Fusion” construct, Lenti-CD44s-luciferase, was then
made by PCR-amplifying the CD44s fragment from
our pTracer construct[7] and subcloning it into Lenti-
luciferase. The fusion protein expressed comprises
CD44s with luciferase at its C-terminal end. The
“Separate” construct, Lenti-CD44s-RSV-luciferase, was
made by inserting an RSV promoter between CD44s
and luciferase sequences to drive luciferase expression.
This construct expresses separate CD44s and luciferase
proteins. PC-3M cells were infected with the 3 respec-
tive constructs to yield PC-3M-luciferase cells, PC-3M-
CD44s-Fusion cells, or PC-3M-CD44s-Separate cells.
Cells were grown in 1 μg/mL puromycin medium. Per-
sistent expression was confirmed by adding luciferin
substrate and imaging the flask on an IVIS 200 system
( X e n o g e n ,A l a m e d a ,C A ) ,a n db yw e s t e r nb l o ta n a l y s i s
prior to use.
Four shRNA constructs were made for knocking down
CD44 variant 9 (longest exon of CD44v7-10). Three
sequences were generated by Extractor 4 computer pro-
gram, and the fourth was from our prior publication[3].
Sequences were cloned into pSuper-RETRO (OligoEn-
gine, Seattle) derived from pSuper[10].
2×1 0
6 293T cells were plated per 10 cm dish, and
grown to 80% confluence in complete growth medium
the next day. For luciferase-only and CD44s, 293T
cells were transfected with Lentivector, packaging plas-
mid (psPAX2), and envelope plasmid (pMD2.G) using
3:1 PEI:DNA. For RNAi against CD44v7-10, the pSu-
per-RETRO with the construct was transfected simi-
larly, but with 3 packaging vectors pJK3, pTAT2, and
pVSVG, to produce retrovirus. After 48 h, supernatant
was harvested and filtered with a 0.45 μm syringe fil-
ter. Incubation with viral supernatant for 2 days was
used to infect the PC-3M cells. Cells were passaged
into a 75 cm
2 flask and supplied with puromycin to
final concentration of 1 μg/ml. A stable cell line was
maintained by changing this selection medium every 3-
7 days.
Plasmid pUHD10-3 that contained EcoR1 fragments
for wild-type merlin cDNA was a gift of Dr. D. H. Gut-
mann of Washington University in St. Louis[11]. PCa
cells were transfected using PEI in the same manner as
the 293T cells. To alter p21-activated kinase-2 (PAK-2),
on which merlin phosphorylation depends in DU145
cells[12], sense and antisense nucleotides were trans-
fected as described[13] with PEI.
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To confirm altered CD44 expression, we used a primer
+ probe set that detects CD44 total, or a set that detects
CD44v7-10 (Applied Biosystems, Foster City, CA) as
described[14]. Detection of 18S ribosomal RNA was
done simultaneously as a normalizer. TaqMan data were
analyzed by the 2
() CT method[14] to determine fold
change in gene expression (untreated cells = 1.00). The
ΔCT was taken as the difference between the CD44v or
CD44 total CT and the 18S ribosomal RNA CT.T h e
ΔΔCT was obtained using the mean ΔCT of untreated
cells as calibrator. Each TaqMan result was compared to
1.00 using 2-tailed paired t-test.
Migration and invasion assays
We used a population of PC-3M cells stably infected
with lentivirus (for CD44s) or pSUPER-derived retro-
virus (for CD44v RNAi). Invasion was assessed with tri-
plicate 24-well Matrigel two-tier invasion chambers, and
migration was assessed with control inserts, both with
8.0 μm pore diameter (Collaborative Biomedical Pro-
ducts, Bedford, MA)[4]. Untreated cells or those expres-
sing a construct were seeded at 30,000 per well. Cells in
the upper insert were in serum-free basal medium
(RPMI 1640 with 0.1% BSA, 4 mM L-glutamine, 100
μg/mL each of penicillin G and streptomycin). The
lower chamber contained chemoattractant medium con-
sisting of 10% fetal bovine serum, 20% conditioned med-
i u mf r o ms u b c o n f l u e n tc u l t u r e ,a n d7 0 %c o m p l e t e
medium. The incubation was carried out 24 h in 5%
CO2 incubator at 37°C. The medium from the upper
inserts, together with non-invading cells were removed
off the upper Matrigel surface. The lower surface was
fixed in methanol and stained with May-Grunwald stain
(Sigma) according to manufacturer’s protocol.
Soft agar colony formation and growth assays
A bottom layer was formed using 2 ml complete med-
ium with 1% agarose that was poured into each well of
6-well plates and solidified at 4°C. PC-3M cells with or
Figure 1 Constructs used for CD44s re-expression in Lentivector. CD44s was expressed as a fusion protein with luciferase, or as a separate
protein. CD44s in human prostate includes exons 1-5 and 16-18, with a small portion of 20, according to our sequencing[3].
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plete medium with 0.5% agarose and seeded as a top
layer. The agarose was solidified at 4°C and then incu-
b a t e da t3 7 ° C .O nd a y1 4 ,t h ec o l o n i e sw e r es t a i n e d
with 1 ml of PBS containing 0.5 mg/ml of p-iodonitrote-
trazolium violet (Sigma, St. Louis, MO). Only live cells
convert this into a colored product. The total number of
colonies from 20, 100× microscopic fields was counted.
For growth assays, we seeded 30,000 cells per 6-well
plate well and harvested and counted cells 3 days later
by grid method.
Cellular adhesion assays
Assays were carried out as described[15] using trypsi-
nized confluent untreated or virally treated cells. Each
test condition was set in 8 wells and each experiment
repeated twice. 96-well black-edged clear flat bottom
Costar plates (Cole-Parmer, Vernon Hills, IL) were
coated with optimal concentrations of ligands[15] using
8 wells to test each one, at 37°C overnight. As controls,
8 wells were coated with 1 mg/ml BSA to measure base-
line nonspecific binding. 1 × 10
6 cells suspended in 1 ml
PBS were incubated with the dye BCECF-AM (Dojindo,
Tokyo) for 15 min at 37°C. After two washes of the cells
with PBS, cells with serum-free basal medium were
a d d e dt op l a t e sa tad e n s i t yo f3×1 0
4 per well and
incubated at 37°C for 90 min. Fluorescence intensities at
5 3 0n mw e r em e a s u r e du s i n gaB i oT e kF L - 6 0 0p l a t e
reader. Non-adherent cells were removed with 2 PBS
washes. Fluorescence intensities with PBS in the wells
were measured. Adhesion was calculated[15] as % cells
bound = (100) fluorescence intensity post-wash/fluores-
cence intensity of total cells plated.
Western blot analysis
Cultured cells were directly lysed in dishes using RIPA
buffer (Upstate Biologicals, Lake Placid, NY) plus the
protease inhibitor mini tablets (Applied Science, India-
napolis, IN). Protein concentration of the cell lysate
was estimated by Bradford method. SDS-PAGE was
performed on 25 μg sample/lane according to Laemmli
method[16] using the NuPAGE system (Invitrogen,
C a r l s b a d ,C A ) .1 0μl of Kaleidoscope protein marker
(Bio-Rad, Hercules, CA) was run in at least one lane.
After electrophoresis for 2 hr, the protein was trans-
ferred to PVDF. Mouse monoclonal antibodies all used
at 1 μg/mL were: to assess overexpressed CD44v7-10,
CD44v10 antibody (Bender MedSystems, Burlingame,
CA); CD44 total (standard + variant 156-3C11), CD44s
( L a b V i s i o n ,F r e m o n t ,C A ) ,a n dr a b b i tm e r l i na n dp h o s -
opho-merlin (Cell Signaling) were used at 1:1000. Anti-
b-actin antibody (Sigma, St. Louis) was used at a dilu-
tion of 1:5,000. Membranes were washed 3 × 10 min
in TBS with 0.1% Tween-20 (TBST) and 1:1000 dilu-
tion of goat anti-mouse IgG antibody labeled with bio-
tin (Bio-Rad) or 1:1,250 goat anti-rabbit (Santa Cruz
Biotechnology, Santa Cruz, CA) was added in 5% skim
milk for 1 h. After washing membrane with 1× TBST,
reactivity was detected using a chemiluminescent sys-
tem (SuperSignal West Pico Substrate, Pierce Biotech-
nology, Rockford, IL). Each experimental run was
conducted at least twice.
Docetaxel Sensitivity Assays
Cells were seeded on a 96-well plate containing 5000
cells/well for 6 h. Docetaxel (Taxotere, Sanofi Aventis,
Bridgewater, NJ) was administered to wells at doses
from 0-50 nM. After 72 hours, MTS assay (CellTiter
96AQ, Promega, Madison, WI) for proliferation was
performed and read on the Bio Tek. The plate was read
at hourly intervals and the representative interval was
chosen for each cell type so as to normalize intensity at
time zero. Even so, the OD values at time zero ranged
from 1.4 to 1.7 and had to be re-normalized before ana-
lysis. The assay was repeated twice with similar results.
Xenograft Growth
Experiments were performed with the approval of the
University of Colorado Denver Animal Care and Use
Committee, 2007, and in conformity with national
guidelines. A total of 32 NIH-III nude mice were used,
including at least 7 per treatment group. 1.5 × 10
6 PC-
3M-luciferase cells, CD44s-Separate cells, CD44s-Fusion
cells, or CD44v7-10 RNAi cells, mixed 1:1 with Matrigel,
were injected subcutaneously into the flank. Presence or
absence of tumor ‘take’ was recorded, and tumor length,
width, and height were measured daily. When tumor
reached 2.0 cm in greatest dimension, mice were imaged
on the IVIS 200 (Xenogen) to confirm persistent signal
in all tumors, prior to mouse sacrifice.
Statistical Analyses
For in vitro assays and mice growth, data were
expressed as mean ± SD. The significance of differ-
ences among group means was tested by two-tailed 2-
sample Student t-test. Statistical significance was set at
p < 0.05.
Results
Establishment of altered CD44 expression
Western blot analyses for total human CD44 (Figure 2)
in CD44s-Separate cells and CD44s-Fusion cells con-
firmed CD44s overexpression. Western blot analysis for
CD44v7-10 was inadequate, since the antibodies we
tested were not reliable. By Real Time RT-PCR, CD44
total was increased 1.80-fold in CD44-Fusion cells and
4.35-fold in CD44-Separate cells compared to untreated
cells. CD44s re-expression as a fusion or separate pro-
tein did not affect CD44 variant. CD44v7-10 re-expres-
sion was reduced to 0.21 (79% silencing) in the 1522
v i r a lR N A ic o n s t r u c t .I nt h i s transfectant, knockdown
was the best among 3 RNAi constructs, so we used it
for all further work.
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PC-3M CD44s-Fusion cells, CD44s-Separate cells, and
CD44v7-10 RNAi cells all displayed >50% decreases in
both migration and invasion compared with the lucifer-
ase-only PC-3M control (Figure 3). Compared to the
luciferase-only control cells, the CD44s-Separate cells
had 86% less migration and 74% less invasion (p <
0.001). The CD44s-Fusion cells showed 78% decreased
migration and 55% decreased invasion (p < 0.001).
Attached cell growth and anchorage-independent growth
Compared to PC-3M-luciferase only cells, attached cell
growth at 3 days was decreased in CD44s-Separate cells
and CD44s-Fusion cells grown in puromycin-containing
medium (both p < 0.001) but not in CD44v7-10 RNAi
cells (p = 0.22, Figure 4). In soft agar assays, the same
trends were evident, with 25% decreases in colonies
formed from CD44s-Separate (p < 0.023) and CD44s-
Fusion (p < 0.002) but not CD44v7-10 RNAi cells (p =
0.156) (Figure 5).
Cell adhesion assay
Increases of about 4-fold in percent cells binding to hya-
luronan, and 3-fold in percent cells binding to osteo-
pontin were noted with the CD44s-Separate cells (p <
0.001) compared to luciferase-only controls. The
CD44s-Fusion cells showed a divergent response, with a
minimal but significant increase in hyaluronan binding
but no increase in osteopontin binding. Both CD44s
infected cell lines and CD44v7-10 RNAi cells had
slightly increased adhesion to fibronectin (Figure 6).
Docetaxel sensitivity assay
Increased sensitivity to Docetaxel doses of 5-50 nM was
achieved in all treated cells, compared to PC-3M lucifer-
ase-only control cells. PC-3M CD44v7-10 RNAi cells
were very sensitive (p < 0.05) across a 5-50 nM dose
range. PC-3M CD44s-Fusion cells were significantly
more sensitive at 5-25 nM, and PC-3M CD44s-Separate
cells only at 5 nM. Benign BPH-1 cells were assessed as
a very sensitive positive control (Figure 7).
Xenograft growth
Tumor take for PC-3M control cells was 9/12 (75%), 7/8
(88%) for CD44s-Separate cells, but only 4/7 (57%) for
CD44s-Fusion cells, and 4/7 (57%) for PC-3M CD44v7-
10 RNAi cells. Tumor latency was defined as days until
appearance of a 0.04 ml palpable mass. Appearance of a
fully-formed mass was defined according to the smallest
of the masses that developed among animals with tumor
take, giving a set point of 0.85 ml. Mean number of
days until these 2 points were reached was calculated
for each cell type (Figure 8). There was no significant
difference among the 4 groups by log-rank test (p =
0.89), but pairwise comparisons showed non-significant
trends toward efficacy for all three therapies, particularly
CD44v7-10 RNAi.
Relationship of CD44 with Merlin
Enforced expression of merlin increased CD44 total in
CD44s-Separate cells (Figure 2). We also examined the
degree of overexpression of merlin and phospho-merlin
achievable in CD44s-Separate cells, compared to lucifer-
ase-only or CD44s-Fusion cells (Figure 9). Total merlin
content was increased the most in CD44s-Separate cells.
Immunoblotting for phospho-merlin, confirmed by the
manufacturer to be phospho-specific to P-Ser 518,
demonstrated a great increase in a band representing
hypophosphorylated, 75 kD merlin in CD44s-Separate
cells. The luciferase-only cells and CD44s-Fusion cells,
in contrast, had less 75-kD, hypophosphorylated form as
Figure 2 Detection of total CD44, by monoclonal antibody in PC-3M cells. The appearance of a predominant cleavage product at 75 kD
(lane 1) rather than a higher molecular weight form, is expected based on our experience [1-4,14]. Re-expression of CD44s as a Fusion protein
with luciferase produced a 137 kD form, with some residual 75-kD form, probably cleaved off after trypsinizing. The forced expression of CD44’s
intracellular binding partner merlin potentiated the increased CD44s (lane 5).
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lation at multiple sites.
Dependence of Phospho-merlin on PAK2
To determine whether expression of the phospho-merlin
were dependent on PAK2, as is the case in DU145 cells
[12], PC-3M cells were transfected with merlin and with
PAK2 antisense oligonucleotide or a sense sequence.
Antisense against PAK2 in luciferase-only PC-3M cells
was effective, and profoundly decreased phospho-merlin
(Figure 10).
Discussion
We have shown that in aggressive PC-3M PCa cells, re-
expression of CD44s greatly reduced invasion, migra-
tion, and tumor cell proliferation, suggesting a number
of functional effects in PCa and possibly certain other
cancers such as bladder, for which CD44s functions as a
tumor suppressor.
In vitro, PCa growth and soft agar colony formation
were inhibited more effectively by CD44s-Separate than
any other treatment. This finding is consistent with
Orian-Rousseau et al., who found, using rat pancreas
cells, that overexpression of the CD44s cytoplasmic tail
was able to inhibit pro-growth Met-Ras-ERK signaling
[17]. It also explains why CD44s-Fusion was not
associated with increased merlin, since the C-terminus
luciferase would render inaccessible the amino acids
292-300 that bind merlin (and ERM proteins). Further-
more, this blockage of binding in CD44s-Fusion cells
would explain the lack of increase in growth-inhibiting
hypophosphorylated merlin after merlin transfection
(Figure 8). With colon cancer cells, conversely, CD44s
h a da na n t i - a p o p t o t i ce f f e c ti nv i v o ,y e tC D 4 4 sk n o c k -
down did not affect proliferation in vitro[15]. Lastly, two
recent papers concern neuroendocrine cells in prostate
cancer. The studies used the IM7 rat monoclonal anti-
body against HCAM/PgP, and the DF1485 mouse
monoclonal antibody against HCAM/PgP. Both of these
antibodies are raised against lymphocyte membrane and
product information shows they detect a 90-kD protein
consistent with CD44s. When we used the DF1485, it
w a st od e t e c tC D 4 4 s[ 1 4 ] .T h e s ea n t i b o d i e sd on o t
detect the epithelial CD44v8-10 or the v7-10 of non-
neuroendocrine prostate cancer. In neuroendocrine car-
cinoma, a rare prostate tumor composed entirely of
neuroendocrine cells, CD44s immunostaining was very
strong[18], whereas in non-neuroendocrine carcinoma
only scattered cells were CD44s-positive as shown pre-
viously[5,6] and those same cells marked as neuroendo-
crine cells[18,19]. Because CD44s marks prostatic stem
Figure 3 The expression of CD44 as a Separate or Fusion protein, or enactment of CD44v7-10 RNAi, all significantly decreased
invasion (Matrigel insert) and migration (control insert) of PC-3M cells. p-values are indicated above bars.
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derived from them, and CD44s may exert an influence
different from its role in non-neuroendocrine cancer
cells, detailed here.
Invasion and migration were strongly inhibited
through CD44s overexpression, and more weakly but
significantly through knockdown of CD44v7-10, as we
showed previously[3]. Interpretation of the latter finding
could be limited, because although the luciferase-only
control cells controlled for a nonspecific effect of viral
infection, PCa infection to express CD44v7-10 sense
strand as a control for off-target effect was not per-
formed. Invasion was assessed through Matrigel mem-
branes, which have no hyaluronan but do have
fibronectin, consistent with Gao’s observation that
CD44s suppression of invasion and metastasis does not
rely on hyaluronan binding[20].
Altered CD44 expression also affected ligand binding,
with increased hyaluronan binding in the CD44s-Sepa-
rate cells compared to CD44s-Fusion. As an explanation,
the mature form of human CD44s lacks the protein pro-
duct of exon 19 but contains most of exon 20 at its
cytoplasmic, C-terminus. A functional C-terminus is
required not only for CD44 binding to ankyrin[21] but
also for hyaluronan binding by the “link” domain at the
N-terminus[22] which involves oligomerization[23], and
for formation of the pericellular matrix[22].
We previously determined that CD44v7-10 was func-
tionally significant for PCa invasion[3] and is increased
by calcitonin, a pro-growth paracrine hormone[14].
CD44 variants are known to oligomerize, causing pro-
growth signaling[23], but in the current studies, the
CD44v7-10 did not appear significant for in vitro,
anchorage-dependent or independent growth or xeno-
graft growth. CD44v7-10 RNAi did not affect merlin or
phospho-merlin, consistent with this lack of an observed
effect on growth. However, RNAi enforced against
CD44v7-10 was most effective for chemosensitization of
PC-3M cells. Docetaxel sensitivity by MTS assay was
maximal in these cells. This result affirms an anti-
Figure 4 The PC-3M-CD44s-Separate cells and CD44s-Fusion cells both showed decreased growth, assessed by growth assays of
30,000 cells after 3 days. CD44v7-10 RNAi cells did not show decreased growth. Untreated cells were killed by puromycin (positive control). p-
values are indicated above bars.
Figure 5 Colony formation of PC-3M in soft agar after 14 days.
The CD44-Separate and CD44 Fusion cells grew significantly fewer
colonies than controls, but CD44v7-10 RNAi cells did not. p-values
are indicated above bars.
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T-cell leukemia cells, for instance, are made refractory
to Fas-mediated apoptosis by their expression of
CD44v6 and v9 isoforms [24], and CD44v7 in rat adeno-
carcinoma cells confers apoptosis resistance by tumor
cell-matrix cross-talk [25]. Growth is also stimulated by
CD44 variants since they uniquely multimerize with and
facilitate the hepatocyte growth factor-Met interaction,
resulting in ERK activation[17].
CD44s-Separate cells and CD44v7-10 RNAi cells,
despite having dramatic anti-growth or pro-chemosensi-
tivity properties in vitro, showed only non-significant
trends toward slower mouse subcutaneous xenograft
growth. Altered expression of other cell adhesion mole-
cules has been described to cause divergent in vitro and
in vivo effects. For example, in thyroid cancer, expres-
sion of CEACAM1, a molecule also involved in both
adhesion and cell signaling for growth pathways, facili-
tated invasion but slowed growth of tumor xenografts
[26]. However, two limitations of our study are sample
size (n = 7 or 8 per group with altered CD44), and not
having tested orthotopic xenografts. Orthotopic grafts,
in a different stromal and matrix metalloprotease micro-
environment, are often slower-growing, non-metastatic,
and respond to certain therapies that subcutaneous ones
do not[27]. We tried to overcome this limitation by use
of Dunning rat PCa cells, in which subcutaneous grafts
can metastasize to lungs[18] but re-expression of human
CD44s as a fusion or separate protein could not be
documented on western blot analysis, and human
CD44v was absent (data not shown), possibly because a
few CD44 bases differ between human and rat. Thus,
our use of the subcutaneous approach may have pre-
cluded assessment of relevant therapeutic effects.
Merlin, a downstream signaling effector of CD44, is
phosphorylated under growth-promoting conditions and
dephosphorylated under growth-inhibiting conditions
including CD44-hyaluronan binding[11,28]. Depho-
sphorylation inactivates it by a conformational change
to a circularized form. In PC-3M cells, using a phospho-
specific antibody, we detected a band representing hypo-
phosphorylated merlin. The band was at 70 kD, as
opposed to the expected 75 kD, and was dependent on
PAK2, as shown by knockdown of PAK2 (Figure 10).
This band was greatly strengthened in CD44s-Separate
cells, suggesting it might facilitate the increased hyaluro-
nan binding of CD44s-Separate cells. However, fully
phosphorylated, active merlin inhibits CD44-hyaluronan
Figure 6 Cell adhesion assay of PC-3M cells. CD44s-Separate cells showed a 4-fold increase in hyaluronan binding and a 3-fold increase in
osteopontin binding compared to luciferase-only cells. CD44s-Fusion cells showed a less marked but significant increase in hyaluronan binding,
but not osteopontin binding. Fibronectin binding was slightly but significantly increased in all infected cells. p values are indicated above bars.
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Page 8 of 12Figure 7 Chemosensitivity by MTS assay. PC-3M cells with CD44v7-10 RNAi were maximally sensitive to Docetaxel doses up to 50 nM.
Moderate increases in sensitivity were noted after re-expression of CD44s as a Separate or Fusion protein. * indicates p < 0.05. As a control,
benign BPH-1 prostate cells were also highly sensitive.
Figure 8 Non-significant reductions in growth of subcutaneous xenografts in nude mice were noted in all treated cells, by Kaplan-
Meier analysis. Daily tumor volume was measured, and two cut points were chosen: 0.04 ml for formation of a palpable mass, and, based on
the smallest tumor among mice with tumor take, 0.85 ml for a fully-formed tumor. n = number of mice with tumor take.
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Page 9 of 12binding[28] so our detection of this form suggests that
in PC-3M cells, CD44s stabilizes merlin in a hypopho-
sphorylated state that is growth-inhibitory yet permits
CD44s-hyaluronan binding. The CD44s-Fusion cells
have their cytoplasmic C-terminus blocked by the
attached luciferase, correlating with less phospho- and
total merlin, and less hyaluronan binding. The increased
binding to osteopontin by CD44s-Separate, but not
CD44s-Fusion, suggests thataf u n c t i o n a lC - t e r m i n u s
may also faciliate osteopontin binding. Interestingly, the
increased osteopontin adhesion in CD44s-Separate cells
disagrees with a previous conclusion that CD44 variants,
but not CD44s, facilitated osteopontin binding to allow
migration[29]; however, these data were based on rat
pancreatic carcinoma, rat fibrosarcoma, and mouse mel-
anoma cells, and pertained to CD44v4-7, not CD44v7-
10.
Horiguchi et al. [12] found that silencing of CD44
dephosphorylates merlin in benign cells, and that merlin
was strongly expressed and constitutively phosphory-
lated in DU145 PCa cells but weak to absent in LNCaP,
PC3, 22RV1, and LAPC-4. Silencing total CD44 in
Figure 9 Enforced expression of merlin increases total merlin and the predominant, lower molecular weight, hypophosphorylated
form of p-merlin (lane 2), and these effects are potentiated in virally-infected CD44s-Separate cells (lane 3). This effect is minimal in CD44s-
Fusion cells (lane 4). Merlin overexpression also markedly increases CD44 total (Figure 2). Together, findings suggest that CD44s-merlin binding
reduces degradation of both molecules.
Figure 10 Antisense inhibition of PAK2 causes a decrease in p-merlin in PC-3M cells. PAK2 is an enzyme that phosphorylates (and
activates) merlin; thus, the preferentially expressed hypophosphorylated form of merlin in PC-3M cells depends on PAK2, as it does in DU145
cells[12].
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Page 10 of 12DU145 cells did not affect merlin and phospho-merlin.
However, our enforced merlin expression in PC-3M-
luciferase cells resulted in increased CD44s. Enforced
CD44s-Separate, in turn, increased the hypophosphory-
lated merlin compared to the minimal, mostly hyper-
phosphorylated amount in PC-3M-luciferase cells
(Figure 2). This may reflect mutual stabilization of
CD44s bound to merlin.
Finally, we considered the attractive prospect of alter-
ing both CD44s and CD44v7-10. It was not possible,
under our system, to establish doubly-infected cells for
CD44s and CD44v7-10-RNAi, because both rely on pur-
omycin for selection, and flow cytometry for luciferase
is not feasible.
Conclusions
The stable re-expression of CD44s reduces PCa growth
and invasion in vitro, and causes a non-significant
growth reduction in the subcutaneous xenograft model.
When the C-terminus of CD44s is fused to another pro-
tein, some phenotypic changes are lessened. Finally,
CD44v7-10, although it was not functionally significant
for growth, may be a target for chemosensitization.
These findings suggest the potential for CD44 altera-
tions in gene therapy, perhaps in conjunction with
enforced alterations of the expression of other
molecules.
Abbreviations
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